Equity Overview
Price & Market Data
Price: $1.35
Daily Change: $0.00 / 0.00%
Daily Range: $1.25 - $1.41
Market Cap: $50,787,712
Daily Volume: 487,966
Performance Metrics
1 Week: -2.88%
1 Month: -15.62%
3 Months: -16.67%
6 Months: -43.51%
1 Year: 1.50%
YTD: -16.67%
Company Details
Employees: 119
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in EmeryVille, California.